DLD Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

DLD Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,096	Closed	-$2.72M	–	469
2025 Q3	$2.72M	Buy	+27,096	New	+$2.44M	0.2%	84

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

DLD Asset Management's XBI Position: Q4 2025 in Review

DLD Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2025, closing a stake of 27,096 shares — an estimated $2.72M sold.

DLD Asset Management first reported a position in XBI in Q3 2025 and held it in 1 quarter. The position peaked at $2.72M in Q3 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q4 2025.

DLD Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2025 after selling out during the quarter.
DLD Asset Management sold 27,096 State Street SPDR S&P Biotech ETF shares in Q4 2025, an estimated $2.72M.
DLD Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2025 and held it in 1 quarter.
DLD Asset Management's State Street SPDR S&P Biotech ETF position peaked at $2.72M in Q3 2025.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.

Based on DLD Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.